These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23666852)

  • 1. IRF4 promotes cell proliferation by JNK pathway in multiple myeloma.
    Zhang S; Xu J; Wu S; Wang R; Qu X; Yu W; Li J; Chen L
    Med Oncol; 2013; 30(2):594. PubMed ID: 23666852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IRF4 in multiple myeloma-Biology, disease and therapeutic target.
    Agnarelli A; Chevassut T; Mancini EJ
    Leuk Res; 2018 Sep; 72():52-58. PubMed ID: 30098518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IRF4 addiction in multiple myeloma.
    Shaffer AL; Emre NC; Lamy L; Ngo VN; Wright G; Xiao W; Powell J; Dave S; Yu X; Zhao H; Zeng Y; Chen B; Epstein J; Staudt LM
    Nature; 2008 Jul; 454(7201):226-31. PubMed ID: 18568025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.
    Ohguchi H; Hideshima T; Bhasin MK; Gorgun GT; Santo L; Cea M; Samur MK; Mimura N; Suzuki R; Tai YT; Carrasco RD; Raje N; Richardson PG; Munshi NC; Harigae H; Sanda T; Sakai J; Anderson KC
    Nat Commun; 2016 Jan; 7():10258. PubMed ID: 26728187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.
    Ikeda S; Kitadate A; Abe F; Saitoh H; Michishita Y; Hatano Y; Kawabata Y; Kitabayashi A; Teshima K; Kume M; Takahashi N; Tagawa H
    Cancer Sci; 2017 Apr; 108(4):641-652. PubMed ID: 28164410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis.
    Low MSY; Brodie EJ; Fedele PL; Liao Y; Grigoriadis G; Strasser A; Kallies A; Willis SN; Tellier J; Shi W; Gabriel S; O'Donnell K; Pitt C; Nutt SL; Tarlinton D
    Cell Rep; 2019 Nov; 29(9):2634-2645.e5. PubMed ID: 31775034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.
    Agnarelli A; Mitchell S; Caalim G; Wood CD; Milton-Harris L; Chevassut T; West MJ; Mancini EJ
    Hematol Oncol; 2022 Aug; 40(3):417-429. PubMed ID: 35544413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.
    Ikeda S; Tagawa H
    Cancer Sci; 2021 Oct; 112(10):3995-4004. PubMed ID: 34310776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IRF4: Immunity. Malignancy! Therapy?
    Shaffer AL; Emre NC; Romesser PB; Staudt LM
    Clin Cancer Res; 2009 May; 15(9):2954-61. PubMed ID: 19383829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma.
    Cheung CHY; Cheng CK; Leung KT; Zhang C; Ho CY; Luo X; Kam AYF; Xia T; Wan TSK; Pitts HA; Chan NPH; Cheung JS; Wong RSM; Zhang XB; Ng MHL
    Blood Adv; 2024 May; 8(9):2217-2234. PubMed ID: 38457926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
    Ishiguro K; Kitajima H; Niinuma T; Ishida T; Maruyama R; Ikeda H; Hayashi T; Sasaki H; Wakasugi H; Nishiyama K; Shindo T; Yamamoto E; Kai M; Sasaki Y; Tokino T; Nakase H; Suzuki H
    Haematologica; 2019 Jan; 104(1):155-165. PubMed ID: 30171029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells.
    Vora AA; Mondala PK; Costello C; MacLeod AR; Crews LA
    STAR Protoc; 2021 Jun; 2(2):100565. PubMed ID: 34136833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon regulatory factor 4 (IRF4) is overexpressed in human non‑small cell lung cancer (NSCLC) and activates the Notch signaling pathway.
    Qian Y; Du Z; Xing Y; Zhou T; Chen T; Shi M
    Mol Med Rep; 2017 Nov; 16(5):6034-6040. PubMed ID: 28849037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUM1/IRF4: A Review.
    Gualco G; Weiss LM; Bacchi CE
    Appl Immunohistochem Mol Morphol; 2010 Jul; 18(4):301-10. PubMed ID: 20182347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption.
    Mondala PK; Vora AA; Zhou T; Lazzari E; Ladel L; Luo X; Kim Y; Costello C; MacLeod AR; Jamieson CHM; Crews LA
    Cell Stem Cell; 2021 Apr; 28(4):623-636.e9. PubMed ID: 33476575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma.
    Bolomsky A; Ceribelli M; Scheich S; Rinaldi K; Huang DW; Chakraborty P; Pham L; Wright GW; Hsiao T; Morris V; Choi J; Phelan JD; Holewinski RJ; Andresson T; Wisniewski J; Riley D; Pittaluga S; Hill E; Thomas CJ; Muppidi J; Young RM
    Cancer Cell; 2024 Jul; 42(7):1185-1201.e14. PubMed ID: 38906156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.
    Ueno N; Nishimura N; Ueno S; Endo S; Tatetsu H; Hirata S; Hata H; Matsuoka M; Mitsuya H; Okuno Y
    Oncogene; 2017 Aug; 36(31):4481-4497. PubMed ID: 28368411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
    Lopez-Girona A; Heintel D; Zhang LH; Mendy D; Gaidarova S; Brady H; Bartlett JB; Schafer PH; Schreder M; Bolomsky A; Hilgarth B; Zojer N; Gisslinger H; Ludwig H; Daniel T; Jäger U; Chopra R
    Br J Haematol; 2011 Aug; 154(3):325-36. PubMed ID: 21707574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
    Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
    J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.